Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations
Abstract
Prostate cancers with mutations in genes involved in homologous recombination (HR), most commonly BRCA2, respond favorably to PARP inhibition and platinum-based chemotherapy. We investigated whether other prostate tumors that do not harbor deleterious mutations in these particular genes can similarly be deficient in HR, likely rendering those sensitive to HR-directed therapies.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 18, 2020
- Source ID
- 10.1158/1078-0432.ccr-19-2135
Entities
People
- István Csabai
- Judit Börcsök
- Marcin Krzystanek
- Mark M. Pomerantz
- Matthew L Freedman
- Miklos Diossy
- Orsolya Rusz
- Sándor Spisák
- Viktoria Tisza
- Zoltán Szállási
- Zsófia Sztupinszki
Organizations
- Boston Children's Hospital
- Dana–Farber Cancer Institute
- Danish Cancer Society
- Eötvös Loránd University
- Novo Nordisk Fonden
- Semmelweis University
- The Breast Cancer Research Foundation